These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2092121)

  • 21. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
    Cappellari A; Bagarella M; Corradi G
    Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fundamental and clinical evaluation of immunoradiometric assay (IRMA) for serum pancreatic oncofetal antigen (POA)].
    Ohba N; Hashimoto T; Nishibu M; Kashiwaya Y; Kawai K; Matsubara F; Miyazaki I
    Rinsho Byori; 1989 Feb; 37(2):153-8. PubMed ID: 2733181
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study of CA15-3 in human breast cancer].
    Nihei M; Nomizu T; Tsuchiya A; Abe R
    Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):987-95. PubMed ID: 3480326
    [No Abstract]   [Full Text] [Related]  

  • 26. [CA50].
    Kawabe T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():645-6. PubMed ID: 16149601
    [No Abstract]   [Full Text] [Related]  

  • 27. Serum marker combinations in human breast cancer (review).
    Lamerz R; Stieber P; Fateh-Moghadam A
    In Vivo; 1993; 7(6B):607-13. PubMed ID: 8193281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tumor markers in breast cancer].
    Harada Y; Ohuchi N; Ishida T; Ohnuki K
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new tumor marker MCA in breast cancer diagnosis.
    Eskelinen M; Tikanoja S; Collan Y
    Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tumor markers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor markers in breast cancer (review).
    Jotti GS; Bombardieri E
    Anticancer Res; 1990; 10(1):253-8. PubMed ID: 2185687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer mucin antigen (BCM) determination by IMX: a preliminary study of epidemiological distribution of the serum levels in gynecological diseases.
    Torre GC; Barbetti V; Lanfranco E; Robutti M; Foglia M; Corongiu F; Vigliercio GP
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):59-62. PubMed ID: 2092151
    [No Abstract]   [Full Text] [Related]  

  • 33. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of plasma in serum tumour marker assays: cancer-associated serum antigen and mammary serum antigen.
    Devine PL; Quin RJ
    Eur J Clin Chem Clin Biochem; 1994 Aug; 32(8):629-30. PubMed ID: 7819434
    [No Abstract]   [Full Text] [Related]  

  • 35. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl Tn antigen: (1). Evaluation of assay conditions and normal values. STN Study Group].
    Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3213-9. PubMed ID: 2782915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
    Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
    Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of CA15/3 serum levels in breast cancer patients.
    Gion M; Mione R; Dittadi R; Fasan S; Pallini A; Bruscagnin G
    J Nucl Med Allied Sci; 1986; 30(1):29-36. PubMed ID: 3462353
    [No Abstract]   [Full Text] [Related]  

  • 39. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
    Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS
    Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer and tumor markers.
    Castellaro E; Francioni S; Pastore M
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):43-7. PubMed ID: 2092148
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.